Organization | Cancer Research UK

Cancer Research UK Report issue

Foundation Phase 1 Phase 2 Phase 3

Founded: London United Kingdom (2002)

Organization Overview

First Clinical Trial

2002

NCT00002460

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Cancer Research UK | Cancer Research UK Cambridge Institute | Cancer Research UK Centre, Southampton University Hospitals and University of Southampton, Southampton SO16 6YD | Cancer Research UK (CRUK) | Cancer Research UK Edinburgh Centre | Cancer Research UK, Glasgow | Cancer Research UK Medical Oncology Unit, Southampton General Hospital, | Cancer Research UK, The Institute of Cancer Research, London, UK | Cancer Research UK & UCL Cancer Trials Centre | Liz-Anne Lewsley

Active Ingredients

Drugs in Phase 3 Trials (69)

125-iodine (1 trial)

2-fluoropyrimidine (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

anastrozole (arimidex) (3 trials)

autologous hematopoietic stem cells (3 trials)

bevacizumab (avastin) (4 trials)

bleomycin (blenoxane) (3 trials)

bone marrow derived mesenchymal stem cells (1 trial)

busulfan (Myleran) (2 trials)

camostat mesylate (1 trial)

capecitabine (xeloda) (10 trials)

carboplatin (paraplatin) (15 trials)

cediranib (3 trials)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (20 trials)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (16 trials)

cytarabine (cytosar-u) (5 trials)

dacarbazine (dtic-dome) (2 trials)

darbepoetin alfa (aranesp) (1 trial)

daunorubicin (cerubidine) (1 trial)

dexamethasone (4 trials)

docetaxel (taxotere) (2 trials)

donepezil (aricept) (1 trial)

doxorubicin (Doxil) (7 trials)

epirubicin (ellence) (2 trials)

erlotinib (tarceva) (2 trials)

etoposide (vepesid) (8 trials)

Filgrastim (neupogen) (3 trials)

fludarabine (fludara) (9 trials)

fluorouracil (efudex) (10 trials)

Fosgemcitabine (acelarin) (1 trial)

ganetespib (2 trials)

gemcitabine (gemzar) (14 trials)

gemtuzumab ozogamicin (mylotarg) (2 trials)

goserelin (zoladex) (1 trial)

ibandronate (boniva) (1 trial)

ifosfamide (ifex) (4 trials)

imatinib (gleevec) (1 trial)

inotuzumab ozogamicin (besponsa) (2 trials)

ixazomib (ninlaro) (2 trials)

lapatinib (tykerb) (2 trials)

lenalidomide (revlimid) (2 trials)

leucovorin (8 trials)

levoleucovorin (fusilev) (1 trial)

melphalan (alkeran) (7 trials)

mitomycin (mutamycin) (1 trial)

mitoxantrone (novantrone) (2 trials)

naltrexone (revia) (4 trials)

octreotide (sandostatin) (1 trial)

olaparib (lynparza) (7 trials)

oxaliplatin (eloxatin) (10 trials)

paclitaxel (taxol) (21 trials)

prednisone (meticorten) (7 trials)

procarbazine (matulane) (1 trial)

quizartinib (1 trial)

red blood cells (1 trial)

rituximab (rituxan) (9 trials)

saracatinib (1 trial)

sargramostim (leukine) (6 trials)

sorafenib (nexavar) (1 trial)

stem cells (1 trial)

tamoxifen (nolvadex) (4 trials)

thalidomide (Thalomid) (4 trials)

trastuzumab (herceptin) (1 trial)

vinblastine (velban) (2 trials)

vincristine (oncovin) (10 trials)

vitamin d3 (2 trials)

Drugs in Phase 2 Trials (67)

124i-meta-iodobenzylguanidine (1 trial)

[18f]fluoropivalate ([18f]fluoro-2,2-dimethylpropionic acid) (1 trial)

abiraterone (zytiga) (1 trial)

acit-1 (1 trial)

afatinib (gilotrif) (1 trial)

alemtuzumab (campath) (4 trials)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

allogeneic lymphocytes (3 trials)

amg-319 (1 trial)

atezolizumab (Tecentriq) (1 trial)

autologous umbilical cord blood (1 trial)

axitinib (inlyta) (1 trial)

azd-4547 (2 trials)

azd-5672 (4 trials)

azd6738 (2 trials)

bi-1206 (1 trial)

bis-choline tetrathiomolybdate (1 trial)

bryostatin (1 trial)

carmustine (bicnu) (3 trials)

chadox1-magea3-nyeso (1 trial)

choline c11 (choline c-11) (1 trial)

crizotinib (xalkori) (1 trial)

cyclosporine (sandimmune) (3 trials)

decitabine (dacogen) (1 trial)

defactinib (1 trial)

durvalumab (imfinzi) (3 trials)

everolimus (zortress) (1 trial)

exemestane (aromasin) (2 trials)

fluoromethylcholine (18f) (FCH) (1 trial)

fulvestrant (faslodex) (2 trials)

glucarpidase (voraxaze) (1 trial)

hmbd-001 (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ipilimumab (yervoy) (1 trial)

irinotecan (Camptosar) (3 trials)

irosustat (1 trial)

letrozole (femara) (2 trials)

megestrol (megace) (1 trial)

methylprednisolone (medrol) (1 trial)

modified vaccinia ankara-5t4 vaccine (2 trials)

mva-magea3 (1 trial)

mycophenolate (CellCept) (1 trial)

nelfinavir (viracept) (1 trial)

nintedanib (ofev) (1 trial)

ofatumumab (arzerra) (1 trial)

osimertinib (tagrisso) (1 trial)

palbociclib (ibrance) (1 trial)

paricalcitol (zemplar) (1 trial)

pegylated arginine deiminase (1 trial)

pembrolizumab (keytruda) (4 trials)

rimantadine (flumadine) (1 trial)

rucaparib (rubraca) (1 trial)

sapitinib (1 trial)

selumetinib (Koselugo) (6 trials)

se-methyl-seleno-l-cysteine (1 trial)

sitagliptin (januvia) (1 trial)

sunitinib (sutent) (1 trial)

tanespimycin (2 trials)

temozolomide (temodar) (3 trials)

topotecan (hycamtin) (2 trials)

tt-702 (1 trial)

vandetanib (caprelsa) (3 trials)

varlilumab (1 trial)

vismodegib (erivedge) (1 trial)

vistusertib (4 trials)

vitamin c (4 trials)

Drugs in Phase 1 Trials (36)

1rg-cart (1 trial)

99mtc demobesin-4 (1 trial)

aldesleukin (Proleukin) (1 trial)

AST-VAC2 (1 trial)

astx660 (1 trial)

at13148 (1 trial)

at9283 (2 trials)

atovaquone (mepron) (1 trial)

azd-0424 (1 trial)

azd3965 (1 trial)

bononophenylalanine (1 trial)

bt1718 (1 trial)

buparlisib (1 trial)

chi lob 7/4 (1 trial)

cxd101 (1 trial)

di-b4 (1 trial)

ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine (1 trial)

enadenotucirev (1 trial)

fludeoxyglucose f-18 (1 trial)

gsk-1070916 (1 trial)

HPV16-E7-T512 (1 trial)

ima950 (1 trial)

iobenguane sulfate i-131 (1 trial)

ly3143921 (1 trial)

mannitol (Osmitrol) (1 trial)

mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes (1 trial)

mk-0752 (1 trial)

mk-1775 (1 trial)

mov18 ige (1 trial)

mva-ebna1/lmp2 vaccine (1 trial)

oxi4503 (1 trial)

suramin (1 trial)

tretinoin (Retin-A) (1 trial)

vadimezan (1 trial)

Drugs in Other Trials (3)

dextrose (1 trial)

ibuprofen (motrin) (1 trial)

zoledronic acid (zometa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Adenocarcinoma, Clear Cell (Phase 2)

Adenomyoepithelioma (Phase 2)

Anus Neoplasms (Phase 2)

Biliary Tract Neoplasms (Phase 3)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Burkitt Lymphoma (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Acinar Cell (Phase 3)

Carcinoma in Situ (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Carotid Body Tumor (Phase 1)

Central Nervous System Neoplasms (Phase 1)

Cholangiocarcinoma (Phase 3)

Choriocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 3)

Dementia (Phase 3)

Disease Progression (Phase 3)

Endodermal Sinus Tumor (Phase 3)

Endometrial Neoplasms (Phase 3)

Enteropathy-Associated T-Cell Lymphoma (Phase 2)

Epstein-Barr Virus Infections (Phase 1)

Esophageal Neoplasms (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Frailty (Phase 3)

Gallbladder Neoplasms (Phase 3)

Germinoma (Phase 3)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hemangiosarcoma (Phase 2)

Hodgkin Disease (Phase 3)

Immunoblastic Lymphadenopathy (Phase 2)

Intestinal Neoplasms (Phase 2)

Kidney Neoplasms (Phase 3)

Laryngeal Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Lymphoproliferative Disorders (Phase 1)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Mucositis (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Nasopharyngeal Carcinoma (Phase 1)

Nasopharyngeal Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Nervous System Neoplasms (Phase 1)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 1)

Neurotoxicity Syndromes (Phase 2)

Oropharyngeal Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 3)

Paraganglioma (Phase 1)

Parkinson Disease (Phase 3)

Pheochromocytoma (Phase 1)

Plasmacytoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 3)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Seminoma (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 3)

Teratoma (Phase 3)

Testicular Neoplasms (Phase 3)

Thyroid Diseases (Phase 3)

Thyroid Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Uveal Neoplasms (Phase 2)

Virus Diseases (Phase 1)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 176
# of Trial APIs: 175